Lin Chien-Chung, Huang Wei-Lun, Wei Fang, Su Wu-Chou, Wong David T
a 1 Department of Internal Medicine, Institute of Clinical Medicine, National Cheng Kung University, Hospital, College of Medicine , Tainan, Taiwan.
b 2 UCLA - Dentistry, 73-034 CHS UCLA School of Dentistry , 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
Expert Rev Mol Diagn. 2015;15(11):1427-40. doi: 10.1586/14737159.2015.1094379. Epub 2015 Sep 30.
Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations. However, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.
肺癌靶向治疗的进展使得基因突变检测成为可能，特别是表皮生长因子受体（EGFR）基因突变。检测方法很大程度上依赖于获取肿瘤组织活检样本，这种方法具有侵入性，并且由于肿瘤异质性或治疗过程中因获得性耐药而发生的变化，可能无法反映治疗时肿瘤的基因组特征。液体活检是一种检测癌细胞或肿瘤DNA证据的血液检测方法，因其能够检测EGFR突变而备受关注。然而，其临床应用受到复杂采集方法和对技术依赖平台需求的限制。最近，已经开发出了用于检测尿液或唾液样本中EGFR突变的更简单技术。本综述重点关注液体活检的进展，并讨论其在肺癌临床应用中的潜力。
